Holen Sie sich die Stockscreener-App
30.80
4.44%
-1.43
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALKS?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$32.23
Offen:
$32.11
24-Stunden-Volumen:
2.28M
Relative Volume:
1.18
Marktkapitalisierung:
$5.08B
Einnahmen:
$1.51B
Nettoeinkommen (Verlust:
$333.35M
KGV:
15.79
EPS:
1.95
Netto-Cashflow:
$315.22M
1W Leistung:
-1.85%
1M Leistung:
+12.45%
6M Leistung:
+13.24%
1J Leistung:
+9.65%
1-Tages-Spanne:
$30.40
$32.29
1-Wochen-Bereich:
$30.40
$32.40
52-Wochen-Spanne:
$25.16
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Firmenname
Alkermes Plc
Sektor
Telefon
00-353-1-772-8000
Adresse
CONNAUGHT HOUSE, DUBLIN 4
Vergleichen Sie ALKS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
30.80 | 5.27B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
143.26 | 63.58B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.88 | 43.58B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.20 | 40.83B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.63 | 23.07B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
432.69 | 19.61B | 3.08B | 1.24B | 1.07B | 25.61 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-26 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-15 | Eingeleitet | Goldman | Buy |
| 2025-06-17 | Hochstufung | UBS | Neutral → Buy |
| 2025-05-28 | Eingeleitet | Needham | Buy |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | Hochstufung | UBS | Sell → Neutral |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-11-05 | Hochstufung | Stifel | Hold → Buy |
| 2024-06-17 | Eingeleitet | TD Cowen | Buy |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-20 | Herabstufung | UBS | Neutral → Sell |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-10-24 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-10-17 | Eingeleitet | UBS | Neutral |
| 2022-11-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-08-16 | Eingeleitet | Piper Sandler | Neutral |
| 2022-04-22 | Fortgesetzt | Goldman | Buy |
| 2022-04-20 | Eingeleitet | Goldman | Buy |
| 2022-01-27 | Hochstufung | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | Eingeleitet | Citigroup | Neutral |
| 2021-10-07 | Hochstufung | Jefferies | Hold → Buy |
| 2021-09-02 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-10-15 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-07-30 | Herabstufung | Goldman | Neutral → Sell |
| 2020-02-14 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-02-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-01-31 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | Hochstufung | Goldman | Sell → Neutral |
| 2019-05-31 | Eingeleitet | H.C. Wainwright | Neutral |
| 2019-05-01 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-12-19 | Herabstufung | Goldman | Neutral → Sell |
| 2018-12-14 | Eingeleitet | Wolfe Research | Underperform |
| 2018-12-13 | Herabstufung | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | Eingeleitet | Piper Jaffray | Neutral |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-06-21 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Alkermes Plc Aktie (ALKS) Neueste Nachrichten
(ALKS) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Alkermes EVP Hopkinson sells $283,776 in shares By Investing.com - Investing.com Nigeria
Alkermes EVP Hopkinson sells $283,776 in shares - Investing.com India
Order flow analysis tools used on Alkermes plcWeekly Risk Report & Target Return Focused Picks - newser.com
Why Alkermes plc stock appeals to analystsMarket Trend Report & Real-Time Price Movement Reports - newser.com
Can Alkermes plc stock deliver consistent earnings growthNew Guidance & Free Real-Time Volume Trigger Notifications - newser.com
Earnings call transcript: Alkermes Plc forecasts strong proprietary sales in Q2 2025 - Investing.com Australia
Real time breakdown of Alkermes plc stock performanceJuly 2025 PreEarnings & Low Risk High Reward Ideas - newser.com
What technical models suggest about Alkermes plc’s comeback2025 Buyback Activity & Long Hold Capital Preservation Tips - newser.com
Is Alkermes plc (8AK) stock cheap vs fundamentalsJuly 2025 Catalysts & Risk Controlled Stock Pick Alerts - newser.com
Is Alkermes plc (8AK) stock at risk of policy regulationJuly 2025 Momentum & Accurate Entry and Exit Point Alerts - newser.com
Historical volatility pattern of Alkermes plc visualized2025 Geopolitical Influence & AI Driven Price Predictions - newser.com
What analysts say about Alkermes plc 8AK stockInstitutional Buying Trends & Next-Level Stock Intelligence, Now Free - earlytimes.in
Is Alkermes plc stock reversal real or fakeJuly 2025 Spike Watch & Accurate Buy Signal Alerts - newser.com
Alkermes Plc (ALKS) Stock Analysis: Investor Outlook With A 33.82% Potential Upside - DirectorsTalk Interviews
Is now a turning point for Alkermes plcQuarterly Portfolio Summary & Trade Opportunity Analysis - newser.com
Full technical analysis of Alkermes plc stock2025 Volume Leaders & Long-Term Capital Growth Ideas - newser.com
Is Alkermes plc a good long term investmentDouble Top/Bottom Patterns & Identify Safe Investments - earlytimes.in
Can Alkermes plc stock deliver strong Q4 earningsMarket Risk Summary & Fast Moving Market Watchlists - newser.com
Ranking Alkermes plc among high performing stocks via toolsJuly 2025 Movers & Comprehensive Market Scan Insights - newser.com
Alkermes Plc Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
How cyclical is Alkermes plc (8AK) stock compared to rivalsEarnings Overview Report & Fast Gaining Stock Strategy Reports - newser.com
Pattern recognition hints at Alkermes plc upside2025 Stock Rankings & Daily Market Momentum Tracking - newser.com
Will Alkermes plc (8AK) stock hit Wall Street targetsProduct Launch & AI Powered Market Entry Ideas - newser.com
Is Alkermes Plc (NASDAQ:ALKS) Trading At A 43% Discount? - 富途牛牛
Alkermes upgraded at RBC Capital Markets ahead of key catalyst - MSN
RBC Lifts Price Target on Alkermes to $45 From $44, Keeps Outperform Rating - MarketScreener
Do Options Traders Know Something About Alkermes Stock We Don't? - Yahoo Finance
Robeco Institutional Asset Management B.V. Buys 36,467 Shares of Alkermes plc $ALKS - MarketBeat
Substance Abuse Treatment Market Size, Growth Analysis 2031 - openPR.com
Is Alkermes plc reversing from oversold territoryTrade Risk Assessment & Reliable Breakout Stock Forecasts - newser.com
Technical analysis overview for Alkermes plc stockMarket Weekly Review & Fast Exit/Entry Strategy Plans - newser.com
Alkermes Plc Experiences Evaluation Revision Amidst Mixed Market Signals and Performance Trends - Markets Mojo
Alkermes sued over alleged scheme to block generic Vivitrol - Reuters
Will Alkermes plc (8AK) stock benefit from Fed rate cuts2025 Market Overview & Comprehensive Market Scan Insights - newser.com
What candlestick patterns are forming on Alkermes plcJuly 2025 Patterns & Fast Gain Stock Trading Tips - newser.com
Finanzdaten der Alkermes Plc-Aktie (ALKS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alkermes Plc-Aktie (ALKS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer |
Oct 15 '25 |
Sale |
31.53 |
9,000 |
283,776 |
73,740 |
0.05%
5.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):